Community Practice

Oral versus injectable, local versus systemic, short cycle versus long — BPC-157 has some of the most elaborate community conventions of any peptide, built almost entirely on animal data and repetition rather than human trials.

The peptide world's most familiar growth-hormone pairing runs on a specific logic: two receptors, complementary signaling, and a nightly ritual built largely outside controlled trials.

Intermittent schedules, exercise timing, and the mixture of animal research, mechanistic reasoning, and repetition that shaped today's community conventions.

Elamipretide is now an approved drug for one rare disease at a specific dose — yet the longevity community researches it at very different, usually lower amounts. The gap between the label and the practice is the story.

Tesamorelin is unusual: an FDA-approved drug with a defined regimen and real trial data, used by the community for a different, off-label goal. Comparing the label with the practice is where this one gets interesting.